CoChat

Mining comorbidities of opioid use disorder from FDA adverse event reporting system and patient electronic health records

Open access
Pan, Yiheng, Xu, Rong · 2022 · BMC Medical Informatics and Decision Making

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.

Abstract

Background: Opioid use disorder (OUD) has become an urgent health problem. People with OUD often experience comorbid medical conditions. Systematical approaches to identifying co-occurring conditions of OUD can facilitate a deeper understanding of OUD mechanisms and drug discovery. This study presents an integrated approach combining data mining, network construction and ranking, and hypothesis-driven case–control studies using patient electronic health records (EHRs). Methods: First, we mined comorbidities from the US Food and Drug Administration Adverse Event Reporting System (FAERS) of 12 million unique case reports using frequent pattern-growth algorithm. The performance of OUD comorbidity mining was measured by precision and recall using manually curated known OUD comorbidities. We then constructed a disease comorbidity network using mined association rules and further prioritized OUD comorbidities. Last, novel OUD comorbidities were independently tested using EHRs of 75 million unique patients. Results: The OUD comorbidities from association rules mining achieves a precision of 38.7% and a recall of 78.2 Based on the mined rules, the global DCN was constructed with 1916 nodes and 32,175 edges. The network-based OUD ranking result shows that 43 of 55 known OUD comorbidities were in the first decile with a precision of 78.2%. Hypothyroidism and type 2 diabetes were two top-ranked novel OUD comorbidities identified by data mining and network ranking algorithms. Based on EHR-based case–control studies, we showed that patients with OUD had significantly increased risk for hyperthyroidism (AOR = 1.46, 95% CI 1.43–1.49, p value < 0.001), hypothyroidism (AOR = 1.45, 95% CI 1.42–1.48, p value < 0.001), type 2-diabetes (AOR = 1.28, 95% CI 1.26–1.29, p value < 0.001), compared with individuals without OUD. Conclusion: Our study developed an integrated approach for identifying and validating novel OUD comorbidities from health records of 87 million unique patients (12 million for discovery and 75 million for validation), which can offer new opportunities for OUD mechanism understanding, drug discovery, and multi-component service delivery for co-occurring medical conditions among patients with OUD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12911-022-01869-8

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Workflow of our study. OUD: opioid use disorder; RWR: random walk with restart; HER: electronic health record
Fig. 1 Workflow of our study. OUD: opioid use disorder; RWR: random walk with restart; HER: electronic health recordCC BY · PubMed Central
Fig. 2 The numbers of true positives in 10 deciles of ranked diseases
Fig. 2 The numbers of true positives in 10 deciles of ranked diseasesCC BY · PubMed Central
Fig. 3 Associations of OUD with hyperthyroidism, hypothyroidism and type 2-diabetes. No—adjusted for demographics only, Yes—adjusted for both demographics and known risk factors
Fig. 3 Associations of OUD with hyperthyroidism, hypothyroidism and type 2-diabetes. No—adjusted for demographics only, Yes—adjusted for both demographics and known risk factorsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 12

Metadata

Authors
Pan, Y., & Xu, R.
Affiliations
Case Western Reserve University (US)
Corresponding author
Xu, Rong
Venue
BMC Medical Informatics and Decision Making
Published
2022-06-16
Volume
22
Issue
S2
Pages
155-155
ISSN
1472-6947 (ISSN-L)
OpenAlex
W4283022475
Cited by
11
References
29
Citations by year
2026: 3 · 2025: 2 · 2024: 3 · 2023: 3
FWCI
1.76
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Medical Informatics and Decision Making (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institute on Aging (R01 AG057557, R01 AG061388, R56 AG062272)
  • National Institute on Drug Abuse (CTN-0114, UG1DA049435)
  • Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University (1UL1TR002548-01)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
opioid use disorder, comorbidities, adverse drug reactions, FDA Adverse Event Reporting System, electronic health records, association rule mining, network ranking, hypothyroidism, hyperthyroidism, type 2 diabetes, frequent pattern mining, drug discovery targets, drug repurposing
MeSH terms
Diabetes Mellitus, Type 2, Humans, Hypothyroidism, Opioid-Related Disorders, United States, United States Food and Drug Administration, Comorbidity, Electronic Health Records

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mining comorbidities of opioid use disorder from FDA adverse event reporting system and patient electronic health records. https://app.cochat.ai/papers/10.1186/s12911-022-01869-8
The paper
Pan, Y., & Xu, R. (2022). Mining comorbidities of opioid use disorder from FDA adverse event reporting system and patient electronic health records. BMC Medical Informatics and Decision Making. https://doi.org/10.1186/s12911-022-01869-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.